Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines

Bulletin Express

昨天

Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.

These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1178407621"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178407621\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178407621?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178407621","market":"us","top_or_hot":-1,"title":"Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines","media":"Bulletin Express","content":"<p>Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.</p>\n<p>These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAb&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-13 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.</p>\n<p>These vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1178407621","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178407621","pubTimestamp":1763023341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"Ab&B Bio-Tech(2627)宣布开始流感疫苗I期临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the latest announcement, Investigational New Drug approvals were obtained from the National Medical Products Administration in July 2024 for the quadrivalent candidate and in October 2024 for the trivalent candidate.\nThese vaccines are designed for individuals aged 65 and above who face a higher risk of severe illness from influenza. Both use an MF59-like adjuvant that boosts antibody titers, aiming to enhance protection for older adults. Ab&B Bio-Tech focuses on developing and commercializing innovative vaccines and has a pipeline that includes, among other products, a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}